Latest News

Janssen speeds up guselkumab approval process

New HQ of Morphosys, which developed guselkumab, © MorphoSys AG


by tg

Janssen speeds up US approval of psoriasis antibody guselkumab and targets further indications.

Janssen Research & Development, LLC has accelerated the US market approval process of guselkumab, a human anti-IL-23 antibody licenced from MorphoSys AG, in moderate to severe plaque psoriasis. According to its partner, the Johnson & Johnson affiliate applied a priority review voucher to the guselkumab biologics license application (BLA). In case of a positive decision by the FDA, Janssen expects US approval in Q3/17.

Janssen said it will conduct  three new phase III trials with the anti-inflammatory antibody: a head-to-head efficacy study of guselkumab vs. Novartis’ anti-IL 17A antibody secukinumab (ECLIPSE study) currently enrolling patients in the indication targeted for approval; a study in psoriatic arthritis set to start in Q3/17; and a Phase III programme in Crohn's disease.

Psoriasis is a bull market with 125 million patients worldwide, 20% of which are estimated to have the moderate to severe form.




Evotec expanding at Milton Park campus

According to Evotec, adding a new building by the end of the year, will bring together all the key functions for small molecule discovery and up to...

Transgene reports clinical results of TG4001 plus avelumab

Combination of TG4001 and Merck KGaA’s checkpoint inhibitor avelumab demonstrated anti-tumour activity in patients with previously treated recurrent...

Merry Christmas and a Happy New Year

Centogene and Anylam launch clinical programme

ATTRv is an autosomal dominant condition caused by a pathogenic variant in the TTR gene coding for transthyretin (prealbumin)....

Moderna to file for EU approval of mRNA-1273 vaccine

Modernas primary analysis of the COVE Phase III data was based on 196 cases, of which 185 cases of COVID-19 were observed in the placebo group versus...

Atriva Therapeutics gets €24m from EIB

According to Atriva Therapeutics, the proceeds allow the company to start Phase II testing of its oral MEK inhibitor ATR-002. In preclinical trails,...

Vifor Pharma inks $340m deal with Angion Biomedica Inc.

Under the deal, Zurich-based Vifor Pharma will pay $30m upfront, make a $30m equity investment in Angion Biomedica and hold out the prospect of...